Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: A preliminary study

Hiroshi Fujishima, Jun Shimazaki, Yukiko Yagi, Kazuo Tsubota

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The mechanism in the pathogenesis of diabetic corneal disease is unclear, but aldose reductase may be involved in the corneal disease. We studied the effects of an aldose reductase inhibitor (ARI) on the ocular surface of diabetic patients. Fourteen aphakic or pseudophakic patients with diabetes were treated with orally administered ONO-2235 (150 mg/day). Corneal sensation, vital staining of ocular surface, and tear production were examined before and 3 months after the administration. After a 3-month period of oral ARI, corneal sensation recovered significantly (from 4.1 ± 4.8 to 3.0 ± 3.1 g/mm2; p = 0.015), with parallel improvements in rose bengal and fluorescein staining scores (p < 0.05). Tear break-up time had also improved (p = 0.003). Results of Schirmer's test (p = 0.03) and the cotton-thread test (p = 0.0001) showed significant improvement in tear production. Improvement in the dynamics of tear production may be due to an improvement in corneal sensitivity. An oral ARI can improve corneal epithelial changes caused by diabetes, probably through recovery of corneal sensation and tear production.

Original languageEnglish
Pages (from-to)368-372
Number of pages5
JournalCornea
Volume15
Issue number4
DOIs
Publication statusPublished - 1996

Fingerprint

Aldehyde Reductase
Tears
Corneal Diseases
Staining and Labeling
Rose Bengal
Fluorescein
epalrestat

Keywords

  • Aldose reductase inhibitor
  • Corneal sensation
  • Tear break-up time
  • Tear dynamics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235 : A preliminary study. / Fujishima, Hiroshi; Shimazaki, Jun; Yagi, Yukiko; Tsubota, Kazuo.

In: Cornea, Vol. 15, No. 4, 1996, p. 368-372.

Research output: Contribution to journalArticle

@article{8844e63e71b54cae8ff1e434d786e481,
title = "Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: A preliminary study",
abstract = "The mechanism in the pathogenesis of diabetic corneal disease is unclear, but aldose reductase may be involved in the corneal disease. We studied the effects of an aldose reductase inhibitor (ARI) on the ocular surface of diabetic patients. Fourteen aphakic or pseudophakic patients with diabetes were treated with orally administered ONO-2235 (150 mg/day). Corneal sensation, vital staining of ocular surface, and tear production were examined before and 3 months after the administration. After a 3-month period of oral ARI, corneal sensation recovered significantly (from 4.1 ± 4.8 to 3.0 ± 3.1 g/mm2; p = 0.015), with parallel improvements in rose bengal and fluorescein staining scores (p < 0.05). Tear break-up time had also improved (p = 0.003). Results of Schirmer's test (p = 0.03) and the cotton-thread test (p = 0.0001) showed significant improvement in tear production. Improvement in the dynamics of tear production may be due to an improvement in corneal sensitivity. An oral ARI can improve corneal epithelial changes caused by diabetes, probably through recovery of corneal sensation and tear production.",
keywords = "Aldose reductase inhibitor, Corneal sensation, Tear break-up time, Tear dynamics",
author = "Hiroshi Fujishima and Jun Shimazaki and Yukiko Yagi and Kazuo Tsubota",
year = "1996",
doi = "10.1097/00003226-199607000-00006",
language = "English",
volume = "15",
pages = "368--372",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235

T2 - A preliminary study

AU - Fujishima, Hiroshi

AU - Shimazaki, Jun

AU - Yagi, Yukiko

AU - Tsubota, Kazuo

PY - 1996

Y1 - 1996

N2 - The mechanism in the pathogenesis of diabetic corneal disease is unclear, but aldose reductase may be involved in the corneal disease. We studied the effects of an aldose reductase inhibitor (ARI) on the ocular surface of diabetic patients. Fourteen aphakic or pseudophakic patients with diabetes were treated with orally administered ONO-2235 (150 mg/day). Corneal sensation, vital staining of ocular surface, and tear production were examined before and 3 months after the administration. After a 3-month period of oral ARI, corneal sensation recovered significantly (from 4.1 ± 4.8 to 3.0 ± 3.1 g/mm2; p = 0.015), with parallel improvements in rose bengal and fluorescein staining scores (p < 0.05). Tear break-up time had also improved (p = 0.003). Results of Schirmer's test (p = 0.03) and the cotton-thread test (p = 0.0001) showed significant improvement in tear production. Improvement in the dynamics of tear production may be due to an improvement in corneal sensitivity. An oral ARI can improve corneal epithelial changes caused by diabetes, probably through recovery of corneal sensation and tear production.

AB - The mechanism in the pathogenesis of diabetic corneal disease is unclear, but aldose reductase may be involved in the corneal disease. We studied the effects of an aldose reductase inhibitor (ARI) on the ocular surface of diabetic patients. Fourteen aphakic or pseudophakic patients with diabetes were treated with orally administered ONO-2235 (150 mg/day). Corneal sensation, vital staining of ocular surface, and tear production were examined before and 3 months after the administration. After a 3-month period of oral ARI, corneal sensation recovered significantly (from 4.1 ± 4.8 to 3.0 ± 3.1 g/mm2; p = 0.015), with parallel improvements in rose bengal and fluorescein staining scores (p < 0.05). Tear break-up time had also improved (p = 0.003). Results of Schirmer's test (p = 0.03) and the cotton-thread test (p = 0.0001) showed significant improvement in tear production. Improvement in the dynamics of tear production may be due to an improvement in corneal sensitivity. An oral ARI can improve corneal epithelial changes caused by diabetes, probably through recovery of corneal sensation and tear production.

KW - Aldose reductase inhibitor

KW - Corneal sensation

KW - Tear break-up time

KW - Tear dynamics

UR - http://www.scopus.com/inward/record.url?scp=0029951568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029951568&partnerID=8YFLogxK

U2 - 10.1097/00003226-199607000-00006

DO - 10.1097/00003226-199607000-00006

M3 - Article

C2 - 8776562

AN - SCOPUS:0029951568

VL - 15

SP - 368

EP - 372

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 4

ER -